Skip to main content

Dana Nichols

Executive Director
A creative, motivated, and skilled fundraising professional, Dana is honored to lead the mission of Cannonball Kids’ cancer. Dana has spent the length of her career in the nonprofit sector of Central Florida. She is a graduate of the University of Central Florida’s Burnett Honors College with a degree in mass communications and nonprofit management. Dana furthered her education at Rollins College’s Crummer Business School where she received her Master’s in Business Administration. Dana and her husband Reid live in Altamonte Springs with their two children.
I am guided by the mantra that ‘Consistency Compounds.’
Dana’s Personal Statement
In 2022 I received a call I never expected. I was diagnosed with Stage 1 breast cancer (invasive ductal carcinoma). Days later my husband and I sat in my surgeon’s office as she began talking through my possible paths for treatment…and I thought, oh my gosh, she’s telling me MY options. At CKc we talk about what it’s like for parents to hear that their child has no more options. We fund research that creates these options. We are fighting to make sure that every child with cancer gets as many options and the survival rate as I was lucky enough to have. Breast cancer is extremely well funded – the whole country turns pink in October. That gave me early detection, treatment options, and the peace of mind that my life plans for the next twenty years don’t have to change. I work every day at CKc to bring that same level of comfort to our kids fighting cancer. They deserve it.

A few Things Dana would like you to know

36 Grants Awarded

Since 2014, CKc has awarded grants that provide access to innovative treatment options across the United States, in D.C., Canada, Scotland, and Switzerland.

94% of CKc-funded clinical trials are first-of-their-kind

Pediatric cancers and adult cancers are different. Standard cancer treatments impact children’s bodies differently than adults’ bodies. We prioritize funding treatments designed specifically to treat pediatric cancers while minimizing the brutal side-effects of standard treatments.